COVID-19: PHARMACOLOGICAL AND THERAPEUTIC APPROACHES

  • Mai ES. Ghoneim Faculty of Pharmacy, University of Sadat City, Menofia, Egypt.
  • Bassma M. Ali Arab Academy for Sciences and Technology and Maritime Transport, Alexandria, Egypt.
  • Asmaa A. Khalifa Faculty of Pharmacy, Pharos University, Alexandria, Egypt.

Abstract

gr.jpg


In the end of 2019, SARS-CoV-2, a new virus from Corona viruses family, has been detected in China and was responsible for COVID-19 disease.  This disease has been suddenly and vigorously disseminated among individuals all over the world. Based on genetic vicinity, this novel virus is similar to SARS-CoV and MERS-CoV and it can spread from an unknown animal host to individuals. Many published clinical data and in vitro studies may offer treatment strategies of some effective antiviral and repurposed drugs, including remdesivir, favipiravir, lopinavir/ritonavir, corticosteroids, etc. This narrative review describes current pharmacological proposed treatments for COVID-19 patients and available experimental and clinical studies for these drugs. Eventually, these data may help to explain the most preferable way to treat COVID-19 and lessen the accompanied symptoms and complications.


                                rw21.gif


Peer Review History:


Received 6 November  2020; Revised 25 December; Accepted 4 January, Available online 15 January 2021


UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. 


Received file:blue_23983.gif                Reviewer's Comments:download_logo_r_29189.gif


Average Peer review marks at initial stage: 5.5/10


Average Peer review marks at publication stage: 7.5/10


Reviewer(s) detail:


Dr. DANIYAN Oluwatoyin Michaelorcid22.jpg, Obafemi Awolowo University, ILE-IFE, Nigeria, toyinpharm@gmail.com


Dr. George Zhuorcid22.jpg, Tehran University of Medical Sciences, Tehran, Iran, sansan4240732@163.com


Dr. Nuray Arıorcid22.jpg, Ankara University, Turkiye, ari@ankara.edu.tr


Similar Articles:


USE OF COLCHICINE TO COUNTERACT THE STRONG HYPERINFLAMMATORY STATE INDUCED BY SARS-COV-2


THE RISKS AND ADVANTAGES OF ANTI-DIABETES THERAPY IN THE POSITIVE COVID-19 PATIENT


EUCALYPTUS ESSENTIAL OIL; AN OFF-LABEL USE TO PROTECT THE WORLD FROM COVID-19 PANDEMIC: REVIEW-BASED HYPOTHESES


SUDANESE EXPERIENCE OF HERBAL FORMULAS USED DURING COVID-19 INFECTION


TRADITIONAL TO RECENT APPROACHES IN HERBAL MEDICINE THERAPY OF COVID-19


 

Keywords: Favipiravir, Monoclonal antibodies, Pathophysiology, Remdesivir, SARS-COV-2

Downloads

Download data is not yet available.
Comments

Statistics
136 Views | 72 Downloads
How to Cite
Ghoneim, M. E., B. M. Ali, and A. A. Khalifa. “COVID-19: PHARMACOLOGICAL AND THERAPEUTIC APPROACHES”. Universal Journal of Pharmaceutical Research, Vol. 5, no. 6, Jan. 2021, doi:https://doi.org/10.22270/ujpr.v5i6.514.
Section
Review Articles